WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
SJIF Impact Factor 7.632
Volume 9, Issue 6, 377-390 Review Article ISSN 2278 – 4357

IMPORTANCE OF CHIRALITY IN EFFECT OF ANAESTHETIC ACTIVITY: A REVIEW

Akshay S. Kasabe*, Mayur S. Bhosale and Sagar D. Magar

Pravara Rural College of Pharmacy, Pravaranagar, Loni, Ahmednagar-413736, (Maharashtra), (India).

Article Received on
04 April 2020,
Revised on 24 April 2020,
Accepted on 14 May 2020
DOI: 10.20959/wjpps20206-16259

***Corresponding Author**
Akshay S. Kasabe
Pravara Rural College of Pharmacy, Pravaranagar, Loni, Ahmednagar-413736, (Maharashtra), (India).

ABSTRACT

There is currently away from of a pattern inside the pharmaceutical business towards the occasion of chiral drugs. The numerous molecules can exist as right-handed and left-handed structures that are non-superimposable perfect representations of each other. They are called enantiomers or substances of opposite shape. Such substances additionally are called to be chiral compound (Greek chiros signifying 'handness'). The important good thing about chiral technology lies in its application within the explore for novel chemical lead compound in drug discovery and its appropriate formulation. In anaesthesia practice about quite half of compound is that the chiral compound most of the drugs available in market are in racemates or mixtures of two or more isomers. Out of those just one isomers shows anaesthetics activity and other enantiomers might not or they need other therapeutic activity. The difference in physicochemical properties may be arising from the various isomers, which can have direct respect to biological activity. These differences affect drug metabolism, absorption, excretion, serum protein binding. This review paper gives a quick idea about importance of chirality in anaesthesia and a few important example of anesthetic drug and it is pharmacokinetic and pharmacodynamics aspects of chirality.

KEYWORDS: Chiral, enantiomers, isomers, anaesthetics drug, Chirality.

INTRODUCTION

The potential biological activity (i.e., drug action) of a ‘targeted-drug molecule’ is only dependent on its chemistry characteristics primarily comprise of the character and kind of purposeful moieties; and conjointly the position of such teams inside the molecule. Chirality has become a major role for the synthesis and development of medication. Most of the

medication discovered is chiral. The pharmacologic activity of medication depends principally on its interaction with biological targets like proteins, nucleic acids and bio membranes. This review article gives the basic ideas, pharmacokinetic and pharmacodynamics parts of chirality, and various explicit examples of their application in sedation, related to ongoing advances to clarify the sedative systems.

It's currently well established that the shape of a molecule is usually one of the foremost vital factors touching drug activity. Consequently, the final form of the structure of a molecule may be a vital thought once planning an analogue. Some structural options impose a considerable degree of rigidity on a structure, while others create the structure a lot of versatile. This implies it is important to pharmacologically evaluate individual stereoisomers and racemates. However, the extent to that one will exploit these structural options can rely on our information of the structure and organic chemistry of the target biological system.[1]

Enantiomers are compounds that the three dimensional arrangement of atoms is such they are non-superimposable mirror pictures. Diastereoisomers are all stereo isomeric compounds that are not enantiomers. Thus, the term "diastereoisomer" includes compounds containing double bonds (geometric isomers) additionally as ring systems. In contrast to enantiomers, diastereoisomers exhibit totally different chemistry properties, including, however not restricted to, temperature, boiling purpose, solubility, and natural process behavior. These variations in chemistry properties permit the separation of diastereoisomers from mixtures utilizing commonplace chemical separation techniques, such as column chromatography or crystallization. Enantiomers cannot be separated mistreatment such techniques unless a chiral atmosphere is provided or they are reborn to diastereoisomers.[2] [3]

STEREOCHEMICAL CONCEPTS

At first, enantiomers were distinguished by their ability to rotate the plane of polarized light [Figure 1]. Isomers rotating light to the proper, or in a very clockwise direction, were designated as dextrorotatory, and this was indicated by a (+)-sign before the chemical name (e.g. (+)-amphetamine or dextroamphetamine). The lettered- and l- were formerly accustomed indicate (+) - and (–)-, respectively. They should remember that this method of nomenclature is predicated on a property of the molecule and doesn't provide any information concerning absolutely the configuration or three-dimensional arrangement of atom s round the chiral center. Because rotation of the plane of polarized light could be a property, in cooperation the magnitude and direction of rotation can vary, reckoning on the conditions.

Thus, temperature, solvent, and concentration of the substance are three factors that require to be considered when reporting optical rotations.[4][5] The configuration of chiral drugs can be characterized in absolute terms by Cahn-Ingold-Prelog sequence rule [Figure 2]. Inside the arrangement rule documentation, the substituent atoms connected to chiral Centre are placed in a request of need dependent on their atomic numbers, with the ligand having the absolute best number being allotted the absolute best priority. The molecule is then seen from the side opposite to the group of lowest priority and, an extremely clockwise bearing, the particle is assigned out the R-configuration from the Latin rectus (right). Any chiral atom might be assigned out during along these lines, whose outright stereochemistry has been resolved. Rectus and Sinister allotted to the spatial direction of gatherings at the chiral Centre and do not the heading of revolution of polarized light; thus it's feasible for the isomer to be S(+) or S(-), R(+) or R(-).[6][7]



Figure 1



Figure 2

STEREOSELECTIVITY AND BIOLOGICAL ACTIVITY

An intensive and extensive research distributed till date on ‘drug-design’ has not only established but also paved the way within the specialized aspect of ‘stereochemistry’ of the ‘targeted-drug molecules’. This particular approach has inspired the ‘medicinal chemist’ to tailor-made such newer drug substance(s) within which the right strategically positioning of assorted functional moieties are introduced (or inducted) so they're capable of interacting optimally with either an enzyme or a receptor. Stereo selectivity is seen in drug deposition especially for those procedures which depend on an association with a chiral natural macromolecule e.g., transport process, plasma protein binding and drug metabolism.[8][9][10]

EASSON- STEDMAN HYPOTHESIS

In 1933, Easson and Stedman reasoned that differences in organic movement between enantiomers came about because of particular reactivity of one enantiomer with its receptor. They considered a theory of 3 point interaction with the receptor this is often demonstrated in [Figure 3] for 2 hypothetical enantiomers. The potent enantiomers involved in at least 3 arrangement alignment with the receptor for 2 hypothetical enantiomers. In [Figure 3] A, B, C, D are hypothetical functional group and A', B', C', D' are hypothetical receptor for binding the functional groups only 1 enantiomer in Capable of achieving the right orientation to enable all three functional groups to suit their respective sites on the receptor surface.[11]

The Easson -Stedman Hypothesis expresses that the firmer enantiomer must be associated with an exceedingly least of three intermolecular connections with the receptor surface which the less powerful enantiomer just interact with 2 sites. Easson and Stedman found that amongst aspargine enantiomers, the (+) aspargine had sweet taste; whereas, (-) aspargine had bland taste. This hypothesis suggested that two different enantiomers may have different biological activity. The biological activity from two different enantiomers arises from the various 3D spatial arrangements of the specified for the biological action enantiomers .the compound may only fit with the receptor if it's occupied all the tree receptor – binding sites. consider the chiral molecule with A, B, C, D functional groups and corresponding receptor sites A', B', C', D'. when A interact with A', B interact with B', C interact with C', D interact with D', then only biological activity seen. for the enantiomers of the molecule, A interact with A', B interact with B', and C interact with C', and D interact with A', where optimum biological response might not be the results.[12][13]



Figure 3

CHIRALITY IS RELATED TO ANAESTHESIA

It is pertinent to look at here that variety of volatiles anesthetics viz., halothane, isoflurane, enflurane and also the like essentially contain in each of them an asymmetric atom (i.e., a chiral Centre); therefore, may invariably occur both as (+)-or (–)-enantiomers. It's been a standard practice to create use of those volatile anaesthetics as their racemates commercially; however, another school of thought devised a mean to ascertain and determine the anesthetic characteristics of individual enantiomers. Chirality has relevancy to anesthesia, just because over 1/2 the synthetic agents utilized in anaesthesia practice are chiral drugs. Most of the chiral comp are administered as racemic mixtures, rather than as single pure enantiomers.[9], Therapeutic activity resides mainly in one amongst the enantiomer. The opposite enantiomer can have unfortunate properties, have distinctive medical activities or be pharmacologically dormant. It's more secure to maintain a strategic distance from the work of therapeutically pointless and potentially hurtful enantiomer, called the isomeric counterbalance, inside the medication details. During a racemic blend, two separate medications are being given at the indistinguishable time with various pharmacodynamics and pharmacokinetics. Since amino acids and sugars, the principle building stones of natural macromolecules, are themselves chiral, the proteins and glycoproteins which comprise compounds, receptors, carrier macromolecules, and so forth additionally are chiral. This prompts stereospecific activity and various affinities of enantiomers. The stereo specificity of enantiomers as clarified above has significant implication for pharmacodynamics as well as for pharmacokinetics of medication.[13] Many of the pharmacokinetic forms like retention, tissue conveyance, plasma protein binding, digestion and disposal use biological macromolecules as their intermediaries. For instance, exhibited that, following an intravenous administration of racemic thiopental, both the general plasma clearance and furthermore the volume of distribution at consistent state were fundamentally more for R-thiopental than for S-thiopental. Accordingly, these two key pharmacokinetic qualities of thiopental were both stereo selective. Interestingly, they further demonstrated this is regularly really on the grounds that the R-enantiomer has essentially bigger plasma unbound portion than the S-enantiomer, bringing about its larger distribution and faster clearance.[14]

THALIDOMIDE TRAGEDY

In 1960 in Europe, racemic thalidomide was given to pregnant females to morning sickness. Studies later recommended that these impacts were brought about by the S-enantiomer which the R-enantiomer contained the necessary helpful action. All the more as of late, considers have inferred that the two enantiomers of thalidomide are temperamental and immediately

epimerize to make the racemate in-vivo in people.[15] The in-vitro contemplates showed the hydrolysis items 5-hydroxy-thalidomide and 5'- hydroxy-thalidomide while in-vivo just the 5'-hydroxy metabolite was found, in low conc, in plasma tests from 8 healthy male volunteers who had gotten thalidomide orally This prompted disfigurements in babies and neurotoxic impacts. These were because of S-thalidomide. R-thalidomide contained the ideal remedial movement.[16]



ENANTIOMERS HAVING DIFFERED IN THERAPUTIC ACTIVITY

Required action resides in one enantiomer-antihypertensive (S) - alpha methyldopa. Enantiomers have distinctive medical signs

1. Dextropropoxyphene is pain relieving, levopropoxyphene is antitussive.
2. Levomethorphan is pain relieving, dextromethorphan is antitussive.

Required action is transcendently with one enantiomer, unfavorable impacts with other- Ketamine Beneficial impacts reside in one enantiomer, the other enantiomer having opposing movement: Levo-salbutamol (bronchodilator without pro-inflammatory properties).

Some chiral drug used in anesthetics practices

1. **Single isomers**

a) Etomidate b) Levobupivocaine c) Rupivocaine d) Pancuronium e) Morhine

2. **Two isomers (racemic mixture)**

a) Halothane b) Enflurane c) Isoflurane d) Desflurane e) Thiopental f) Ketamie g) Bupiocaine h) Epinephrine i) Nor Epinephrine j) Dobutamine

3. **More than two isomers**

a) Atracurium b) Mivacurium

ETOMIDATE

(R)-Etomidate is tenfold more impregnable than its (S)-enantiomer. At low concentrations (R)-etomidate could be a modulator at GABAA receptors.[17] Containing β2 and β3[18] subunits. At higher concentrations, it can elicit currents within the absence of GABA and behaves as an allosteric agonist. Its binding site is found within the Trans membrane section of this receptor between the alpha and beta subunits (α−β+). β3-containing GABAA receptors are involved within the anaesthetic actions of etomidate, while the β2-containing receptors are involved in a number of the sedation and other actions which will be elicited by this drug.[19] S-isomer lacks hypnotic activity.



KETAMINE

Ketamine may be a chiral compound. Most pharmaceutical arrangements of ketamine are racemic; be that as it may, a few brands apparently have (for the most part undocumented) contrasts in their enantiomeric extents Ketamine is shown as a sedative for suggested demonstrative and surgeries. In the event that muscle relaxation is required, it should be joined with a relaxant.[20] Ketamine was found in 1962, first tried in in 1964, and endorsed to be utilized inside the us in 1970[21 to 23] The S(+) and R(–) stereoisomers of ketamine attached to the dizocilpine site of the NMDA receptor with various affinities, the past demonstrating roughly 2-to 3-overlap more affinity liking for the receptor than the latter.[24] Ketamine may furthermore cooperate with and hinder the NMDAR through another allosteric site on the receptor.[25] R ketamine: Emmergence reaction like Hallucination, Vivid dreams and Agitation.[26]



(S)- ketamine



(R)- ketamine

THIOPENTAL

Sodium thiopental is an ultra-short-acting barbiturate and has been utilized generally inside the induction period of sedation. Its utilization has been to a great extent supplanted therewith of propofol, however holds as an induction operator for quick arrangement intubation and in obstetrics.[27] S-enantiomers is multiple times very R-enantiomers in potentiation of GABA.[28] However studies have demonstrated that there are simply unassuming distinction in pharmacokinetic properties of enantiomers like clearance and volume of distribution.



BUPIVACAINE

Bupivacaine is the foremost commonly used anesthetic in regional anesthesia during labor, moreover as in postoperative pain management.[29] Long acting sedative agent advertised as 50:50 racemic forms. Reports of death in light of bupivacaine prompted CNS poisonousness and cardio toxicity on unintentional infusion and troublesome revival following cardio toxicity.[30] Ropivacaine is that the principal 'unadulterated' enantiomer containing >99% of the S-form. S-enantiomers are less neurotoxic than bupivacaine. Bupivacaine is more secure is discouraging cardiovascular K+ channels than the S-enantiomers. In this way, levobupivacaine and ropivacaine lesserly affect mean stroke index, ejection fraction.[31] Levobupivacaine is that the (S)-(–)-enantiomer of bupivacaine, with an extended duration of

action, producing less vasodilation. Durect Corporation is developing a biodegradable, controlled-release drug delivery system for after surgery.[32]



HALOTHANE

Halothane sold under the name Fluothane among others, may be an anesthetic agent. It is wont to start or maintain anaesthesia.[33] Halothane may be a chiral molecule that's used as a racemic mixture.[34] By 2005, the first regular unpredictable sedatives utilized were isoflurane, sevoflurane, and desflurane. However, by 2000, sevoflurane, great for inhalation induction, had to a great extent replaced the work of halothane in kids. Individuals are presented to halothane inside the working environment by breathing it in as waste anaesthetic gas, skin contact, eye contact, or swallowed it. The National Institute for Occupational Safety and Health (NIOSH) has set a suggested exposure limit (REL) of two ppm (16.2 mg/m3) over hour.[35] Halothane activates GABAA and glycine receptors.[36] It doesn't affect the AMPA or kainate receptors.[37]



ISOFLURANE

It is wont to start or maintain anaesthesia. It's a racemic mixture of (R) - and (S)-optical isomers. It vaporizes readily, but could be a liquid at temperature.[38] A few investigations

have found S (+) - isoflurane to be half harder than R (-) - isoflurane w.r.t. while different examinations have discovered no critical contrast. Clinical preferences of utilizing S-isoflurane as one enantiomer are insignificant. The two enantiomers are similarly solvent inside the lipid bilayers. S-isoflurane that initiated about half longer sleep times than R-isoflurane. equivalent to many general anesthetics, the exact instrument of the activity has not been unmistakably outlined.[39] Isoflurane diminishes torment affectability (analgesia) and a muscle relaxes. Isoflurane goes about as a +ve allosteric modulator of the GABAA receptor in electrophysiology investigations of neurons and recombinant receptors.[40]



CONCLUSION

The expanding availability of single enantiomer drugs guarantees pharmaceutical researchers to create more secure, better-approved, and progressively effective medications for treating patients. When both a single drug and an underlying disease formulation are available, information from clinical trials and clinical experience should be used to determine which method is appropriate. Issues with respect to the composite character of race drugs are to a great extent disregarded by the creators, prompting the formation of information understandings and their decisions. The pharmaceutical industry and contributors to scientific journals should be given Specific instructions for the characterization of chiral drugs and the pharmacology and toologyology of individual enantiomers. Even specialists or drug specialists some of the time don't have the idea about that there is 'isomeric ballast' in drug utilized for general treatment. In the event that no stereochemistry is thought of, the growing body of medicinal effects of chirality would not be properly interpreted Better stereo chemical understanding Anti-racist sedate issues will support their clinical use. Academically and environmentally, race isn't justified, despite any potential benefits viewed as one medication by drug specialists yet as one 50:50 is a mix of at least two medications.

REFERENCES

1. "Fundamentals of Medicinal Chemistry" By Gareth Thomas University of Portsmouth, UK, http//.wiley.com; 2003 by John Wiley, page No. 59.
2. "Principle of Medicinal Chemistry" by William Foye, 6th Edition, Lippincott Williams & Wilkins, Woltess Kluwear (India) Pvt. Ltd, New Delhi. Page No. 39, [10] Page No. 40-41.
3. Kelly JG, McIlroy PJ. Chemistry. In: Dundee JW, Clarke RS, McCaughey W, Editors. Clinical anaesthetic pharmacology. Edinburgh: Churchill Livingstone; 1991. p. 3-14.
4. Millership J, and Fitzpatrick A. commonly used chiral drugs: a survey. Chirality, 15: 573-576.
5. "Essentials of Pharmaceutical Chemistry" 4th Edition, by Donald Cairns, the Robert Gordon University, Pharmaceutical Press. Page No. 82, 83.
6. Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia, 1956; 12: 81-94.
7. Hill SA. Correct nomenclature for stereoisomers. Anesthesia, 2002; Page No.57.
8. "Medicinal Chemistry" By Ashutosh Kar, 4th edition, New Age International Publication 2007, page no.54, 55.
9. Crossley R, Chirality and the Biological Activity of Drugs, CRC Press, Boca Raton.
10. Stinson S. Counting on chiral drugs. Chem. Eng. News, 76: 83-103.
11. "Medicinal Chemistry" a molecular and biochemical approach by Thomas Nogrady & Donald F. Weaver, 3rd edition, Oxford University press 2005, Page no. 37-39.
12. "Principle of Medicinal Chemistry" by William Foye, 6th Edition, Lippincott Williams & Wilkins, Woltess Kluwear (India) Pvt. Ltd, New Delhi. Page No. 40-41.
13. https://elearning.uniroma1.it/pluginfile.php/604441/mod_folder/content/0/2018-2019/Lessons/10.Lez_2019. Drug%20discovery%2C%20design%20and%20development3.pdf? Force download=1
14. Nguyen KT, Stephens DP, McLeish MJ, Crankshaw DP, Morgan DJ. Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. Anesth Analg, 1996; 83: 552-8.
15. Egan TD. Stereochemistry and anesthetic pharmacology: Joining hands with the medicinal chemists. Anesth Analg, 1996; 83: 447-50.
16. Meyring M, Muhlbacher J, Messer K, Kastner-Pustet N, Bringmann G, Mannschreck A, and Blaschke G. In vitro biotransformation of (R) - and (S)-thalidomide: application of

circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites. Anal. Chem., 74(15): 3726-35.

17. Vanlersberghe, C; Camu, F (2008). "Etomidate and other non-barbiturates". Handbook of Experimental Pharmacology, 182(182): 267–82. Doi: 10.1007/978-3-540-74806-9_13. ISBN 978-3-540-72813-9. PMID 18175096
18. Drexler, B; Jurd, R; Rudolph, U; Antkowiak, B (2009). "Distinct actions of etomidate and propofol at beta3-containing gamma-aminobutyric acid type receptors". Neuropharmacology, 57(4): 446–55. doi:10.1016/j.neuropharm.2009.06.014. PMID 19555700.
19. Chiara DC, Dostalova Z, Jayakar SS, Zhou X, Miller KW, Cohen JB (2012). "Mapping general anesthetic binding site(s) in human α1β3 γ-aminobutyric acid type a receptors with [^{3}H] TDBzl-etomidate, a photoreactive etomidate analogue". Biochemistry, 51(4): 836–47. Doi: 10.1021/bi201772m. PMC 3274767. PMID 22243422.
20. "Ketamine Injection". Drugs.com. Archived from the original on 10 December 2014. Retrieved 1 December 2014.
21. Ketamine – CESAR". Center for Substance Abuse Research. University of Maryland. Archived from the original on 12 November 2013.
22. Strayer, RJ; Nelson, LS (2008). "Adverse events associated with ketamine for procedural sedation in adults". American Journal of Emergency Medicine, 26(9): 985–1028. doi:10.1016/j.ajem.2007.12.005. PMID 19091264. Archived from the original on 8 September 2017.
23. "Ketamine Side Effects". Drugs.com. Archived from the original on 10 December 2014. Retrieved 1 December 2014.
24. Hirota, K; Lambert, DG (October 1996). "Ketamine: Its mechanism(s) of action and unusual clinical uses". British Journal of Anaesthesia, 77(4): 441–4. doi:10.1093/bja/77.4.441. PMID 8942324. Archived from the original on 20 October 2015.
25. Orser, BA; Pennefather, PS; MacDonald, JF (1997). "Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors". Anesthesiology, 86(4): 903–17. Doi: 10.1097/00000542-199704000-00021. PMID 9105235.
26. Bell, RF (June 2012). "Ketamine for chronic noncancer pain: concerns regarding toxicity". Current Opinion in Supportive and Palliative Care., 6(2): 183–7. doi:10.1097/SPC.0b013e328352812c. PMID 22436323.

27. Morgan, DJ; Blackman, GL; Paull, JD; Wolf, LJ (1981). "Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section". Anesthesiology, 54(6): 474–80. doi:10.1097/00000542-198106000-00006. PMID 7235275.
28. Franks, NP; Lieb, WR (23 November 1998). "Which molecular targets is most relevant to general anaesthesia?" Toxicology Letters, 100–101 (1–2): 1–8. Doi: 10.1016/S0378-4274(98)00158-1. PMID 10049127
29. Ma J, Zhang W, Yao S (December 2016). "Liposomal bupivacaine infiltration versus femoral nerve block for pain control in total knee arthroplasty: A systematic review and meta-analysis". Int J Surg, 36(Pt A): 44–55. doi:10.1016/j.ijsu.2016.10.007. PMID 27742564.
30. Weinberg, G; Ripper, R; Feinstein, DL; Hoffman, W. (2003). "Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity". Regional Anesthesia and Pain Medicine, 28(3): 198–202. doi:10.1053/rapm.2003.50041. PMID 12772136.
31. Rosenblatt, MA; Abel, M; Fischer, GW; Itzkovich, CJ; Eisenkraft, JB (July 2006). "Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest". Anesthesiology, 105(1): 217–8. Doi: 10.1097/00000542-200607000-00033. PMID 16810015
32. Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST); "Archived copy". Archived from the original on 2011-12-27. Retrieved 2012-03-01. ClinicalTrials.gov processed this record on February 29, 2012.
33. WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 17–18. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
34. Bricker, Simon (17 June 2004). The Anaesthesia Science Viva Book. Cambridge University Press. p. 161. ISBN 9780521682480. Archived from the original on 10 September 2017 – via Google Books.
35. "CDC - NIOSH Pocket Guide to Chemical Hazards - Halothane". Www.cdc.gov. Archived from the original on 2015-12-08. Retrieved 2015-11-03.
36. Hugh C. Hemmings; Philip M. Hopkins (2006). Foundations of Anesthesia: Basic Sciences for Clinical Practice. Elsevier Health Sciences. pp. 292–. ISBN 978-0-323-03707-5. Archived from the original on 2016-04-30.
37. Paul Barash; Bruce F. Cullen; Robert K. Stoelting; Michael Cahalan; Christine M. Stock; Rafael Ortega (7 February 2013). Clinical Anesthesia, 7e: Print + Ebook with

Multimedia. Lippincott Williams & Wilkins. pp. 116–. ISBN 978-1-4698-3027-8. Archived from the original on 17 June 2016.

38. "Isoflurane (inhalation anaesthetic) - Summary of Product Characteristics (SPC) - (eMC)". Www.medicines.org.uk. 11 January 2016. Archived from the original on 20 December 2016. Retrieved 13 December 2016.
39. "How does anesthesia work?" Scientific American. February 7, 2005. Archived from the original on May 29, 2016.
40. Jones MV, Brooks PA, Harrison NL (April 1992). "Enhancement of gamma-aminobutyric acid-activated Cl- currents in cultured rat hippocampal neurones by three volatile anaesthetics". The Journal of Physiology, 449: 279–93. doi:10.1113/jphysiol.1992.sp019086. PMC 1176079. PMID 1326046